GlassScriptPhysician profile
Geeta Venkat
NPI 1588774954
$4,564.00
in general payments reported to CMS, 2019-2025
25 companies · $753 in 2025
The $753 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $316 · 2021: $633 · 2022: $972 · 2023: $800 · 2024: $659 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,211.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,584.48 | 2019-2025 | |
| Glaxosmithkline, LLC. | $666.49 | 2019-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $623.79 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $319.00 | 2019-2024 | Tezspire |
| Optinose US, INC. | $264.81 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $221.36 | 2020-2025 | |
| Genentech USA, INC. | $149.89 | 2019-2023 | Xolair |
| Pfizer INC. | $119.95 | 2019-2023 | |
| Biocryst US Sales Co., LLC | $82.67 | 2022-2024 | Orladeyo |
| Philips North America LLC | $77.68 | 2019 | |
| Csl Behring | $55.72 | 2024 | Hizentra |
| Ars Pharmaceuticals Operations, INC. | $54.89 | 2025 | Neffy |
| Kaleo, INC. | $49.60 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.21 | 2020-2023 | Takhzyro |
| Grifols USA, LLC | $36.82 | 2023-2024 | Xembify |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $26.97 | 2023 | Opzelura |
| Leo Pharma INC. | $26.17 | 2022 | |
| Depuy Synthes Sales INC. | $25.77 | 2021 | |
| Alk-Abello, INC | $22.35 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.96 | 2021 | |
| Horizon Therapeutics Plc | $20.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.50 | 2020 | |
| Blueprint Medicines Corporation | $18.40 | 2023 | Ayvakit |
| Pharming Healthcare, INC. | $14.42 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geeta Venkat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.